Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Alderuccio, Juan Pablo, Desai, Amrita, Yepes, Monica M., Chapman, Jennifer R., Vega, Francisco, Lossos, Izidore S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889253/
https://www.ncbi.nlm.nih.gov/pubmed/29636930
http://dx.doi.org/10.1002/ccr3.1382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889253/
https://www.ncbi.nlm.nih.gov/pubmed/29636930
http://dx.doi.org/10.1002/ccr3.1382

Ejemplares similares